Skip to main content
Premium Trial:

Request an Annual Quote

RNAi -- From Biology to Therapeutics meeting, Qiagen s BioRobot MDx DSP system, Qiagen s human phosphatase siRNA set and human cancer siRNA set, Wiley s RNA Interference in Practice text

Premium

C5 has scheduled its upcoming RNAi — From Biology to Therapeutics meeting for Jan. 31-Feb. 1, 2005.

The event, which is taking place at the Kempinski Hotel Bristol in Berlin, is slated to include discussions of such topics as microRNAs in the context of diabetes; RNAi in oncology target validation and discovery; the development of siRNA-based therapeutics; delivery of siRNAs in vivo; and alternative approaches to RNAi to silence genes.

Speakers set to attend include Rene Ketting from the Hubrecht Laboratory; Aimee Jackson from Rosetta Inpharmatics; Cenix Bioscience CEO and CSO Chris Echeverri; Antonin de Fougerolles from Alnylam Pharmaceuticals; and Jonathan Hall from the Novartis Institutes for Biomedical Research.

Details about the conference, including registration information, can be found at http://www.C5-online.com/rnai.


Qiagen said this week that it has introduced the BioRobot MDx DSP system, an automated sample preparation system for viral nucleic acids.

According to the company, the system has received approval from the European Union under its recent in vitro diagnostics directive.

The system, running the company’s QIAamp DSP 96 Virus MDx consumables, provides automated purification of viral nucleic acids from human plasma or serum, said Qiagen. The system includes the instrument, software, service, purifications kits, and protocols that provide sample and data tracking and full process documentation, it added.

Qiagen also recently introduced its human phosphatase siRNA set, a collection of siRNAs targeting 222 phosphatase genes. Details on this product can be found at http://www1.qiagen.com/Products/GeneSilencing/LibrarySiRna/SiRnaSets/HumanPhosphatasesiRNASet.aspx.

The company also just launched its human cancer siRNA set version 2, a collection of siRNAs targeting 1183 cancer genes. The company also markets subsets that include siRNAs against apoptosis genes, angiogenesis genes, cell cycle genes, DNA repair genes, growth factor genes, and metastasis genes. Details about these sets can be found at http://www1.qiagen.com/Products/GeneSilencing/LibrarySiRna/SiRnaSets/HumanCancersiRNASet.aspx.


John Wiley & Sons is publishing a new book entitled . RNA Interference in Practice: Principles, Basics, and Methods for Gene Silencing in C. elegans, Drosophila, and Mammals

The text, which is scheduled for release on Dec. 31, is billed as including step-by-step protocols to help the reader learn how RNAi works, how to design efficient RNAi constructs, how to achieve RNAi in cell culture, how to determine the efficiency of an RNAi experiment, and how to use RNAi for gene therapy.

The book was edited by Ute Schepers of the University of Bonn in Germany.